Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Eric P. Winer, MD, of the Dana-Farber Cancer Institute, discuss the results of this study that showed pathologic complete response to presurgery chemotherapy improved survival (Abstract S2-05).
Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, discuss findings on de-escalating systemic therapy for breast cancer (Abstract ES6-3).
Matthew J. Ellis, PhD, FRCP, of the Baylor College of Medicine, gives his expert perspective on this evolving area of research.
Lisa A. Carey, MD, of the University of North Carolina, and Jay Harris, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, discuss Dr. Harris' plenary lecture.
William M. Sikov, MD, of Women and Infants Hospital of Rhode Island, discusses the results of this study that showed pathologic complete response to presurgery chemotherapy improved survival (Abstract S2-05).
Patricia A. Ganz, MD, of the University of California at Los Angeles, discusses this clinical trial of anastrozole vs tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (Abstract S6-04).
